Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-EGFR antibody variable domain is fused to CH1 and the other scFv from an anti-IGF1R antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.